Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERLA: Dostarlimab + chemotherapy vs pembrolizumab + chemotherapy in metastatic non-squamous NSCLC
2023-505894-33-00Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Dostarlimab + platinum/pemetrexed chemotherapy with Pembrolizumab + platinum/pemetrexed chemotherapy (2 arms). Primary endpoint: Objective response rate (ORR) by BICR using RECIST v1.1. Started Feb 2024; status: completed.
02
Drugs
dostarlimabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-505894-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505894-33-00.